<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293239</url>
  </required_header>
  <id_info>
    <org_study_id>EMS Tumor 01</org_study_id>
    <nct_id>NCT02293239</nct_id>
  </id_info>
  <brief_title>Effects of WB-EMS and Dietetic Treatment on Cancer Patients</brief_title>
  <official_title>Effects of Whole-Body Electromyostimulation (WB-EMS) Combined With Individualized Nutritional Support on Patients With Malignant Disease Undergoing Curative or Palliative Anti-cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-N端rnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-N端rnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effects of a 12-week whole-body electromyostimulation (WB-EMS)
      training combined with individualized nutritional support on body composition, muscle
      strength and function and quality of life of patients with malignant disease undergoing
      curative or palliative anti-cancer treatment
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Skeletal muscle mass</measure>
    <time_frame>12 weeks</time_frame>
    <description>Skeletal muscle mass assessed by bioelectrical impedance analysis (in kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical function - Gait pattern</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sensor-based gait analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function - Isometric muscle strength</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hand grip strength assessed by hand dynamometer (in kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function - Endurance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Six-minute-walk test (walking distance in m)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical function - Lower limb strength</measure>
    <time_frame>12 weeks</time_frame>
    <description>30 second sit-to-stand test (number of sit-to-stand cycles)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported performance status</measure>
    <time_frame>12 weeks</time_frame>
    <description>ECOG performance status/Karnofsky index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Quality of Life (QoL)</measure>
    <time_frame>12 weeks</time_frame>
    <description>EORTC QLQ - C30 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Fatigue</measure>
    <time_frame>12 weeks</time_frame>
    <description>FACIT-Fatigue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory blood markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood collection and analysis e.g. of C-reactive protein (CRP), Albumin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cancer</condition>
  <condition>Cancer Cachexia</condition>
  <condition>Weight Loss</condition>
  <condition>Muscle Loss</condition>
  <condition>Muscle Weakness</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>&quot;usual care&quot; control group receives individualized nutritional support (dietary advices: daily protein intake &gt; 1.0 g/kg bodyweight)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WB-EMS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>physical exercise group regular WB-EMS training (2 EMS trainings per week; each session for 20 min)
+ individualized nutritional support (dietary advices: daily protein intake &gt; 1.0 g/kg bodyweight)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whole-Body Electromyostimulation (WB-EMS)</intervention_name>
    <description>WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial</description>
    <arm_group_label>WB-EMS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  malignant disease (solid or hematological cancer): head and neck cancer, colorectal
             carcinoma, small intestinal cancer, gastric cancer, oesophageal cancer, pancreas
             carcinoma, liver cell carcinoma, cholangiocarcinoma,lung cancer, breast cancer, cervix
             cancer, ovarian cancer, prostate cancer, renal cell carcinoma, malignant melanoma,
             patients with leukaemia and malignant lymphomas or Graft-versus-Host-Disease after
             bone marrow transplantation

          -  ongoing or planned curative or palliative anti-cancer therapy

        Exclusion Criteria:

          -  simultaneous participation in other nutritional or exercise intervention trials

          -  acute cardiovascular events

          -  use of anabolic medications

          -  epilepsy

          -  severe neurological diseases

          -  skin lesions in the area of electrodes

          -  energy active metals in body

          -  pregnancy

          -  acute vein thrombosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Klinik 1, University of Erlangen-N端rnberg</name>
      <address>
        <city>Erlangen</city>
        <state>Bavaria / Franconia</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuradg端l Zopf, Prof. Dr. med.</last_name>
      <phone>0049 09131 8535225</phone>
      <email>yurdaguel.zopf@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Hans Joachim Herrmann, Dr. oec. troph.</last_name>
      <phone>0049 09131 8545017</phone>
      <email>hans.herrmann@uk-erlangen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>whole-body electromyostimulation</keyword>
  <keyword>cachexia</keyword>
  <keyword>cancer</keyword>
  <keyword>skeletal muscle mass</keyword>
  <keyword>nutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Cachexia</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

